Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 16/20 | 0.75 |
| ▸ | PIM1 | P11309 | 1/20 | 0.62 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1055715 | 0.87 | FYN (0.81) | FYNPIM1MKNK1 | |
| SCHEMBL1055683 | 0.86 | FYN (1.00) | FYNMKNK1 | |
| SCHEMBL2949134 | 0.86 | FYN (1.00) | FYNPIM1MKNK1 | |
| SCHEMBL2945214 | 0.85 | FYN (1.00) | FYNMKNK1 | |
| SCHEMBL2943456 | 0.85 | FYN (1.00) | FYNPIM1MKNK1 | |
| SCHEMBL18613459 | 0.83 | FYN (1.00) | FYNPIM1 | |
| SCHEMBL4690264 | 0.82 | FYN (0.81) | FYNMKNK1KDM4ENPC1RAB9A | |
| SCHEMBL16332607 | 0.82 | FYN (1.00) | FYNPIM1MKNK1KDM4ENPC1 | |
| SCHEMBL1053098 | 0.82 | FYN (0.77) | FYNMKNK1KDM4ENPC1RAB9A | |
| SCHEMBL2948415 | 0.82 | FYN (0.82) | FYNPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| WO-2007025090-A2 | HETEROBICYCLIC AND - TRICYCLIC INHIBITORS OF MAPK/ERK KINASE | KALYPSYS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049591-A1 | Inhibitors of MAPK/Erk Kinase | KALYPSYS, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049591-A1 | Inhibitors of MAPK/Erk Kinase | KALYPSYS, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049591-A1 | Inhibitors of MAPK/Erk Kinase | KALYPSYS, INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | MAP4K2, MAP3K1, MAP3K2 | FYN 421/4885PIM1 365/4885MKNK1 144/4885 |
| US-20070049591-A1 | Inhibitors of MAPK/Erk Kinase | MAPK1, MAP3K1, MAP3K6 | FYN 322/4885PIM1 157/4885MKNK1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.